Reporter nanoparticle that monitors its anticancer efficacy in real time

Authors:

Abstract
Significance: The ability to identify responders and nonresponders very early during chemotherapy by direct visualization of the activity of the anticancer treatment and to switch, if necessary, to a regimen that is effective can have a significant effect on the outcome as well as quality of life. Current approaches to quantify response rely on imaging techniques that fail to detect very early responses. In the case of immunotherapy, the early anatomical readout is often discordant with the biological response. This study describes a self-reporting nanomedicine that not only delivers chemotherapy or immunotherapy to the tumor but also reports back on its efficacy in real time, thereby identifying responders and nonresponders early on.
Funding Information
  • HHS | NIH | National Cancer Institute (1R01CA135242)
  • DOD | Congressionally Directed Medical Research Programs (BC132168)
  • DOD | Congressionally Directed Medical Research Programs (W81XWH-09-1-0700)
  • American Lung Association (LCD-259932-N)
  • American Cancer Society (122854-PF-12-226-01-CDD)